Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target raised by equities research analysts at Piper Sandler from $70.00 to $83.00 in a report issued on Tuesday, The Fly reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Sandler’s price objective indicates a potential upside of 12.68% from the stock’s current price.

Several other equities analysts have also weighed in on RARE. Robert W. Baird restated a “buy” rating and set a $75.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, April 1st. Citigroup lifted their target price on shares of Ultragenyx Pharmaceutical from $53.00 to $66.00 and gave the company a “neutral” rating in a report on Friday, May 8th. Zacks Investment Research upgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and set a $61.00 target price on the stock in a report on Thursday, April 16th. SunTrust Banks lifted their target price on shares of Ultragenyx Pharmaceutical from $80.00 to $82.00 and gave the company a “buy” rating in a report on Friday, June 19th. Finally, Stifel Nicolaus lifted their target price on shares of Ultragenyx Pharmaceutical from $70.00 to $82.00 and gave the company a “buy” rating in a report on Monday, May 18th. Three analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $77.64.

Shares of NASDAQ RARE traded down $2.92 during trading on Tuesday, hitting $73.66. 375,300 shares of the company traded hands, compared to its average volume of 577,534. Ultragenyx Pharmaceutical has a 1 year low of $31.99 and a 1 year high of $79.67. The company has a 50-day moving average price of $71.53 and a 200-day moving average price of $57.31. The firm has a market capitalization of $4.57 billion, a P/E ratio of -10.02 and a beta of 2.21. The company has a quick ratio of 4.49, a current ratio of 4.54 and a debt-to-equity ratio of 0.06.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($1.91) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.23). Ultragenyx Pharmaceutical had a negative net margin of 348.78% and a negative return on equity of 60.65%. The company had revenue of $36.31 million for the quarter, compared to analysts’ expectations of $36.74 million. During the same period in the prior year, the firm earned ($1.82) earnings per share. The firm’s quarterly revenue was up 99.8% on a year-over-year basis. Research analysts predict that Ultragenyx Pharmaceutical will post -6.43 EPS for the current fiscal year.

In other news, CFO Shalini Sharp sold 7,128 shares of the company’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $73.32, for a total value of $522,624.96. Following the sale, the chief financial officer now owns 122,929 shares in the company, valued at approximately $9,013,154.28. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Matthew K. Fust sold 1,875 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $75.00, for a total transaction of $140,625.00. Following the completion of the sale, the director now owns 55,424 shares in the company, valued at approximately $4,156,800. The disclosure for this sale can be found here. Insiders sold a total of 26,555 shares of company stock worth $1,942,395 in the last quarter. 8.20% of the stock is currently owned by company insiders.

Institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC grew its position in shares of Ultragenyx Pharmaceutical by 1,976.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 706 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 672 shares during the last quarter. Pearl River Capital LLC bought a new stake in shares of Ultragenyx Pharmaceutical during the 1st quarter valued at about $39,000. Advisor Group Holdings Inc. bought a new stake in shares of Ultragenyx Pharmaceutical during the 1st quarter valued at about $43,000. First Mercantile Trust Co. grew its position in shares of Ultragenyx Pharmaceutical by 14.5% during the 1st quarter. First Mercantile Trust Co. now owns 2,161 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 274 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. grew its position in shares of Ultragenyx Pharmaceutical by 189.3% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 2,248 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 1,471 shares during the last quarter. Institutional investors and hedge funds own 99.91% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Featured Story: The Discount Rate – What You Need to Know

The Fly

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.